CENTURY(SZ:300078)2021-04-29 16:00Dividend Distribution - The company plans to distribute a cash dividend of 0.13 RMB per 10 shares to all shareholders, based on a total of 869,411,466 shares[5]. - The cash dividend distribution for 2020 was set at RMB 0.13 per 10 shares, totaling RMB 11,302,349.06, which represents 10.78% of the net profit attributable to shareholders[137]. - The total cash dividend amount for 2019 was RMB 15,649,406.39, with a distribution of RMB 0.18 per 10 shares[137]. - The company has a policy that mandates a minimum of 20% cash dividend distribution during significant capital expenditure phases[134]. Financial Performance - The company's operating revenue for 2020 was ¥1,471,264,743.10, a decrease of 6.53% compared to ¥1,573,993,606.47 in 2019[18]. - The net profit attributable to shareholders for 2020 was ¥104,893,557.97, down 28.94% from ¥147,607,911.10 in 2019[18]. - The net profit after deducting non-recurring gains and losses was ¥31,342,664.40, a decline of 73.82% from ¥119,728,829.88 in 2019[18]. - The net cash flow from operating activities was negative at ¥13,707,363.29, compared to a positive cash flow of ¥4,016,052.21 in 2019, marking a 441.31% decrease[18]. - Total revenue for 2020 was ¥1,471,264,743.10, a decrease of 6.53% compared to ¥1,573,993,606.47 in 2019[65]. - The company achieved operating revenue of 1,471.26 million yuan, a decrease of 6.53% year-on-year; operating profit was 125.42 million yuan, down 23.82%; net profit attributable to shareholders was 104.89 million yuan, a decline of 28.94%[46]. Market and Business Strategy - The company is focused on expanding its market presence and enhancing its product offerings in the healthcare technology sector[11]. - The company aims to enhance patient safety, medical quality, and clinical efficiency through its smart medical solutions, leveraging IoT, big data, and AI technologies[27]. - The company is focused on expanding its smart healthcare ecosystem, which includes smart hospitals, health management, and big data-driven AI services[28]. - The company aims to enhance its market position through the development of intelligent medical platforms and services, targeting various healthcare institutions[82]. - The company is actively pursuing the development of integrated healthcare solutions, as evidenced by the launch of multiple interconnected software platforms[14]. Research and Development - The company is committed to ongoing research and development to innovate new products and technologies in the healthcare field[11]. - The total R&D investment reached 203.1 million yuan, accounting for 13.81% of operating revenue, reflecting a year-on-year growth of 26.02%[36]. - The company focused its R&D expenses on forward-looking business lines such as single-disease AI services, successfully obtaining a patent for an AI invention during the reporting period[47]. - The company has made continuous investments in independent research and development of artificial intelligence technology, solidifying its leading position in the medical AI field with over 60 single-disease data resource databases and applications[38]. - The company is focusing on developing an Industrial IoT platform to enhance service capabilities in the industrial manufacturing sector[76]. Technology and Innovation - The company has implemented advanced technologies such as RFID and IoT to improve its product efficiency and customer experience[11]. - The company has developed proprietary technologies such as the THINKGO+ cognitive engine, which combines advanced big data, AI, and blockchain technologies[38]. - The company’s artificial intelligence medical cognitive engine, THINKGO, is utilized for statistical analysis and modeling of real-world clinical big data[30]. - The company has established a comprehensive IoT platform for smart business solutions, covering supply chain management, retail, manufacturing, and smart cities, and has built long-term partnerships with over 300 global clients[39]. - The company is committed to integrating IoT, AI, and cloud computing technologies to create a comprehensive healthcare service model[116]. Governance and Compliance - The company has established a strong governance structure to ensure compliance and transparency in its operations[11]. - The company is committed to improving its governance structure and risk management practices, ensuring compliance with regulations and enhancing operational efficiency[62]. - The company has not identified any major impacts on its delisting indicators or risk warning indicators due to the identified misstatements[150]. - The independent directors have urged the management to take effective measures to recover the occupied funds and improve the operational environment[153]. Challenges and Risks - The decline in performance was primarily due to increased R&D investment in the smart medical sector, significant business downturn in the business intelligence segment, and new equity incentive expenses[46]. - The company acknowledges potential risks from international trade policies and currency fluctuations, particularly affecting its export business[123]. - The ongoing pandemic poses risks to the company's sales and cash flow, potentially leading to significant performance declines if not controlled[125]. - The company faces intensified competition in the smart medical and commercial intelligence sectors, necessitating continuous technological advancements and market exploration[121]. Investment and Funding - The company raised 817 million yuan through the issuance of convertible bonds, with net proceeds of 805.59 million yuan allocated to various innovative projects, enhancing its market position and operational capabilities[61]. - The company successfully issued 8.17 billion RMB worth of convertible bonds, with 8.17 million bonds at a face value of 100 RMB each, to fund projects in internet + AI medical innovation and marketing system expansion[125]. - The company has committed to using up to RMB 18,000 million of idle raised funds to temporarily supplement working capital, with a usage period not exceeding 12 months[101]. Environmental and Social Responsibility - The company adheres to environmental protection standards, with all emissions within the regulatory limits[189]. - The company actively fulfills its social responsibilities and complies with relevant laws and regulations[188]. - The company has implemented training programs to enhance employee skills and maintain employee rights[187]. - The company has received feedback from the China Securities Regulatory Commission regarding its bond issuance[191]. Shareholder and Equity Management - The company has a long-term commitment not to transfer or entrust the management of its shares within 36 months from the date of listing[141]. - The company has fulfilled its commitments regarding share transfer restrictions and other obligations as of the reporting date[141]. - The total number of shares increased from 859,275,466 to 869,411,466, with an increase of 10,136,000 shares due to the issuance of restricted stock[196]. - The number of restricted shares decreased by 95,389,400, resulting in a total of 34,593,670 restricted shares, which is 3.98% of the total shares[196].